News

NEWS

SOTIO a.s. appoints Chiltern International

SOTIO a.s. has selected Chiltern International Limited to be the Contract Research Organization (CRO) that carries out the European part of its phase III global clinical trial entitled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.

NEWS

SOTIO, a part of PPF Group

SOTIO has become a part of the PPF Group’s portfolio – one of the largest investment and finance groups in Central and Eastern Europe. The administrative process of the transfer of the equity interest was completed towards the end of 2012.

NEWS

Two awards for Radek Špíšek, SOTIO Supervisory Board Member

Doctor Radek Špíšek was on Friday November 16th, 2012 appointed Professor of Medical Immunology by the President of the Czech Republic Václav Klaus. Professor Radek Špíšek together with Prof. Jiřina Bartůňková dedicated more than ten years to research in the field of active cellular immunotherapy and its use in the treatment of cancer.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies